Live Updates: U.S. recommends "pause" for Johnson & Johnson COVID vaccine to review blood clot cases

The Food and Drug Administration and Centers for Disease Control and Prevention are recommending a "pause" in the administration of Johnson & Johnson's single-dose COVID-19 vaccine to review blood clot cases.

The agencies said in a statement Tuesday the CDC will convene a meeting of the Advisory Committee on Immunization Practices on Wednesday to review six cases of "a rare & severe type of blood clot" in people who received the vaccine. The FDA will then review that analysis as it also investigates the cases. "Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution," Dr. Anne Schuchat, principal deputy director of the CDC, and Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said in the statement.